Hereditary papillary renal cell carcinoma
Log in to starLast updated Nov 3, 2026
A patient is diagnosed with bilateral papillary type 1 renal cell carcinoma. Several family members have had similar kidney tumors.
AD; MET (hepatocyte growth factor receptor, a receptor tyrosine kinase; proto-oncogene); activating missense variants, gain of function
MET is a receptor tyrosine kinase on the surface of renal epithelial cells. Its only known ligand is hepatocyte growth factor (HGF), and part of its normal role is repair of the renal tubule after ischemic or chemical injury.
HPRCC runs opposite to most hereditary kidney cancers, which pass on an inactivated tumor suppressor and need the second copy lost in the tumor. Every MET pathogenic allele is a missense variant that activates the receptor: it dimerizes and phosphorylates itself, and the tyrosine kinase domain (amino acids 1110 to 1268) signals without HGF. The constant signal drives the PI3K/AKT/mTOR, STAT, and MEK/ERK pathways, which promote proliferation, survival, and motility. In that respect HPRCC resembles MEN2, the other inherited receptor tyrosine kinase activation.
The result is confined to the kidney: type 1 papillary tumors, bilateral and multifocal (a kidney may hold thousands of microscopic tumors), with lifetime penetrance near 100%. The tumors grow slowly (about 0.15 cm per year), so lesions under 3 cm are watched. Because the driver is the kinase itself, germline carriers responded to the MET inhibitor foretinib in 50% of cases, against 13.5% in the trial overall.
- Type 1 papillary renal cell carcinoma
- Bilateral/multifocal
- No extrarenal manifestations
- Suspect with bilateral, multifocal type 1 papillary RCC, particularly with a family history of papillary kidney tumors
- Histology shows type 1 papillary RCC; the absence of cutaneous, uterine, or other extrarenal findings helps distinguish it from HLRCC and Birt-Hogg-Dube
- Confirm with germline MET testing (activating proto-oncogene variants)
- Renal surveillance with periodic abdominal imaging (MRI preferred to limit cumulative radiation given the lifelong, multifocal risk)
- Active surveillance of small renal masses with nephron-sparing surgery at a ~3 cm threshold, reflecting the relatively indolent course of type 1 papillary tumors
- MET-directed tyrosine kinase inhibitors are an option for advanced or metastatic disease
- Cascade testing of at-risk relatives